Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis
Pharmaceuticals · 16.11.2024 · 17 (11) · 1542
DOI: 10.3390/ph17111542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 16.11.2024. Verfasst von Gareth J Morgan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Boston University Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background/Objectives: Antibody light chains form amyloid fibrils that lead to progressive tissue damage in amyloid light chain (AL) amyloidosis. The properties of each patient’s unique light chain appear to determine its propensity to form amyloid. One factor is N-glycosylation, which is more frequent in amyloid-associated light chains than in light chains from the normal immune repertoire. However, the mechanisms underlying this association are unknown. Here, we investigate the frequency and position within the light chain sequence of the N-glycosylation sequence motif, or sequon.
Methods
Monoclonal light chains from AL amyloidosis and multiple myeloma were identified from the AL-Base repository. Polyclonal light chains were obtained from the Observed Antibody Space resource. We compared the fraction of light chains from each group harboring an N-glycosylation sequon, and the positions of these sequons within the sequences.
Results
Sequons are enriched among AL-associated light chains derived from a subset of precursor germline genes. Sequons are observed at multiple positions, which differ between the two types of light chains, κ and λ, but are similar between light chains from AL amyloidosis and multiple myeloma. Positions of sequons map to residues with surface-exposed sidechains that are compatible with the folded structures of light chains. Within the known structures of λ AL amyloid fibrils, many residues where sequons are observed are buried, inconsistent with N-glycosylation.
Conclusions
There is no clear structural rationale for why N-glycosylation of κ light chains is associated with AL amyloidosis. A better understanding of the roles of N-glycosylation in AL amyloidosis is required before it can be used as a marker for disease risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Boston University Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
- Section of Hematology and Medical Oncology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
- Department of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
ORCID-Profile: Gareth J Morgan, Brian H Spencer, Vaishali Sanchorawala, Tatiana Prokaeva
Förderung
- NHLBI NIH HHS
- NIH HHS
- NCATS NIH HHS
- NIH
Zitieren
APA
Morgan, G. J., Yung, Z., Spencer, B. H., Sanchorawala, V., & Prokaeva, T. (2024). Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis. Pharmaceuticals, 17(11), 1542. https://doi.org/10.3390/ph17111542
Vancouver
Morgan GJ, Yung Z, Spencer BH, Sanchorawala V, Prokaeva T. Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis. Pharmaceuticals. 2024;17(11):1542. doi:10.3390/ph17111542
BibTeX
@article{Morgan2024,
author = {Morgan, Gareth J and Yung, Zach and Spencer, Brian H and Sanchorawala, Vaishali and Prokaeva, Tatiana},
title = {Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {11},
pages = {1542},
doi = {10.3390/ph17111542}
}
EUVIMED